MedWatch

GN intensifies goal: Plans to have at least 25 percent female leaders by 2025

Audio and hearing aid company GN turns up its equality-related ambitions and aims to have at least 25 percent female leaders by 2025. The company plans to accomplish this by, for example, laying down more demands for external recruitment agencies.

Photo: GN Store Nord / PR

It's hardly conducive to innovation if everyone in an executive group looks the same, is the viewpoint of GN Store Nord, which has laid down the goal that it wants at least 25 percent of senior management positions within the company to be occupied by women by 2025, writes newspaper Børsen.

"Afterwards, we will most certainly raise our ambitions. For many companies, it gets more challenging when you're at more than 20 percent. For us, this is driven by the fact that we're an engineer-heavy company, and that the pond which we're fishing in essentially contains more men than women," says Senior Vice President and Head of HR Group at GN Pierre Berkmann.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs